Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632226 | 0.91 | EGFR (0.53) | EGFRCCNA2CDK2CCNA1FGFR1 | |
| SCHEMBL5779004 | 0.89 | EGFR (0.53) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL5632295 | 0.88 | CCNA2 (0.64) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL5629041 | 0.88 | EGFR (0.61) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL14459755 | 0.87 | EGFR (0.57) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL5628559 | 0.85 | EGFR (0.58) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL5628891 | 0.84 | EGFR (0.55) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL5628943 | 0.84 | EGFR (0.56) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL5632249 | 0.84 | EGFR (0.62) | EGFRCCNA2CDK2CCNA1MKNK1 | |
| SCHEMBL5629462 | 0.83 | EGFR (0.55) | EGFRCCNA2CDK2CCNA1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | MKI67, PCNA, MYC | EGFR 1499/4885CCNA2 9/4885CDK2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.